Paul D Price

US Patent:

6579684, Jun 17, 2003

Filed:

Mar 4, 1999

Appl. No.:

09/262213

Inventors:

Paul A. Price - La Jolla CA
Julia S. Johansen - Frederiksberg, DK

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

G01N 33574

US Classification:

435 723, 435 4, 435 71, 435 74, 435 792, 435975, 436501, 436518, 436525, 436 63, 436 64, 436808, 436811, 436813, 5303879, 5303881, 53038885, 5303897, 4241741

Abstract:

This invention is a method of identifying the presence of, and monitoring, a disease state in a mammal which is associated with degradation of connective tissue in the mammal. The method detects and determines whether diagnostically or prognostically significant levels of YKL-40 protein and/or YKL-40 peptide are present in a biological sample. The method can be used, for example, to identify the presence of inflammatory or degenerative joint disease or degeneration of connective tissue in organs. Serum YKL-40 levels as detected and quantified by the inventive method are also suggestive of the prognosis for the length of survival in breast cancer patients following recurrence and/or metastasis of their cancers. The figure shows the elution position of substantially pure serum YKL-40 on a gel filtration column.

US Patent:

6794150, Sep 21, 2004

Filed:

Dec 18, 1998

Appl. No.:

09/215077

Inventors:

Paul A. Price - La Jolla CA
Julia S. Johansen - Copenhagen, DK

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

G01N 3353

US Classification:

435 723, 435 4, 435 71, 435 74, 435 792, 435975, 436501, 436518, 436525, 436 63, 436 64, 436808, 436811, 436813, 5303879, 5303881, 53038885, 5303897

Abstract:

The invention is a method of identifying the presence of, and monitoring, a disease state in a mammal which is associated with degradation of connective tissue in the mammal. The method detects and determines whether diagnostically or prognostically significant levels of YKL-40 protein and/or YKL-40 peptide are present in a biological sample. The method can be used, for example, to identify the presence of inflammatory joint disease or degeneration of connective tissue in organs. Serum YKL-40 levels as detected and quantified by the invention method are also suggestive of the prognosis for the length of survival in breast cancer patients following recurrence and/or metastasis of their cancers.

US Patent:

6812034, Nov 2, 2004

Filed:

Oct 18, 2001

Appl. No.:

10/045596

Inventors:

Paul A. Price - La Jolla CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

G01N 3320

US Classification:

436 79, 436 87

Abstract:

This invention provides methods of inhibiting calcification of a soft tissue (e. g. , an artery, a heart valve, an atherosclerotic plaque, a cancer, a kidney, a prostate, skin, muscle, cartilage, viscera, and heart muscle) in a mammal. These methods involve inhibiting osteoclastic bone resorption in said mammal (e. g. , a mammal diagnosed as having or at risk for a pathology characterized by calcification of a soft tissue). The inhibition is preferably by administration of a bisphosphonate to the mammal in a concentration sufficient to inhibit bone resorption without inhibiting bone mineralization. The methods of this invention can also be used to mitigate a symptom of atherosclerosis in a mammal. Such methods involve inhibiting osteoclastic bone resorption in the mammal. In preferred embodiment, the inhibiting is by administration of a bisphosphonate to the mammal in a concentration sufficient to inhibit bone resorption without inhibiting bone mineralization.

US Patent:

7230086, Jun 12, 2007

Filed:

Aug 25, 2003

Appl. No.:

10/648811

Inventors:

Paul A. Price - La Jolla CA, US
Julia S. Johansen - Frederiksberg, DK

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C07K 16/00

US Classification:

5303881, 5303879, 53038885, 5303897, 436547, 436548

Abstract:

The invention is a method of identifying the presence of a disease state in a mammal which is associated with degradation of connective tissue in the mammal which contains the protein known as YKL-40. The method is a competitive immunoassay for YKL-40. It can be used, for example, to identify the presence of inflammatory or degenerative joint disease and tumor metastasis (to the extent it can be correlated to serum YKL-40 levels). Serum YKL-40 levels as detected and quantified by the inventive method are also suggestive of the prognosis for the length of survival in breast cancer patients following recurrence and/or metastasis of their cancers.

US Patent:

7670599, Mar 2, 2010

Filed:

Mar 4, 2005

Appl. No.:

11/073333

Inventors:

Paul A. Price - La Jolla CA, US
Julia S. Johansen - Frederiksberg, DK

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 39/395

US Classification:

4241301

Abstract:

This invention provides methods for detecting cancers and for evaluating the prognosis of cancer patients. In particular, the methods of this invention utilize YKL-40 as a marker for the presence or absence of a cancer and for the prognosis (e. g. likelihood of recurrence) of a cancer. Elevated levels of YKL-40 are indicative of the presence of a cancer in undiagnosed subjects and indicate likely recurrence of the cancer in subjects diagnosed as having a cancer.

US Patent:

8053563, Nov 8, 2011

Filed:

Feb 16, 2006

Appl. No.:

11/817244

Inventors:

Richard Bonnichsen - Mahe, SC
Paul Price - La Jolla CA, US

Assignee:

BIO-Y A/S

International Classification:

C07K 16/00

US Classification:

5303879, 5303871, 5303881, 5303888, 53038885

Abstract:

The present invention relates to monoclonal anti-human YKL-antibodies which are capable to modulate biological processes in which YKL-40 plays a prominent role, e. g. inhibit the growth and/or inducing apoptosis of cells, in particular cancer cells. The invention also relates to pharmaceutical compositions comprising said antibodies and uses said antibodies and/or pharmaceutical compositions for treatment of a disease wherein inhibition of cell growth, cell differentiation, remodelling of extracellular matrix, metastasis and/or induction of cell death due to apoptosis is a prerequisite for successful curing. An antibody of the invention is capable of inhibiting biological function of YKL-40 in the above mentioned processes by binding to a specific epitope on YKL-40.

US Patent:

20110283919, Nov 24, 2011

Filed:

Jun 4, 2009

Appl. No.:

12/994426

Inventors:

Paul A. Price - La Jolla CA, US

International Classification:

C09D 189/00
C09D 1/00
B65D 85/00

US Classification:

1061601, 206438, 1061241, 10628729

Abstract:

This invention provides novel methods for making mineralized matrices. In certain embodiments methods are provided for forming a crystalline phase within a defined liquid volume. The methods can involve combining a crystallization inhibitor; a solution that would, in the absence of the inhibitor, form the crystalline phase; and a semi-permeable barrier that excludes the inhibitor but allows the solution containing the constituents of the crystalline phase to enter, whereby a crystalline phase is formed within the liquid volume.

US Patent:

20120149882, Jun 14, 2012

Filed:

Dec 2, 2011

Appl. No.:

13/290803

Inventors:

Richard Bonnichsen - Victoria, SC
Paul Price - La Jolla CA, US

International Classification:

C07K 16/40

US Classification:

5303879

Abstract:

The present invention relates to monoclonal anti-human YKL-antibodies which are capable to modulate biological processes in which YKL-40 plays a prominent role, e.g. inhibit the growth and/or inducing apoptosis of cells, in particular cancer cells. The invention also relates to pharmaceutical compositions comprising said antibodies and uses said antibodies and/or pharmaceutical compositions for treatment of a disease wherein inhibition of cell growth, cell differentiation, remodelling of extracellular matrix, metastasis and/or induction of cell death due to apoptosis is a prerequisite for successful curing. An antibody of the invention is capable of inhibiting biological function of YKL-40 in the above mentioned processes by binding to a specific epitope on YKL-40.